Two well-received precision oncology IPOs closed out the week, joined by a successful ophthalmic specialty IPO and an immunotherapy debut that fell flat. P53 mutation hunter PMV Pharmaceuticals Inc. charged out the gate, raising $211.8 million, while Prelude Therapeutics Inc. took in $158.2 million.
DUBLIN – Galecto Biotech Inc. raised $64 million in a series D funding round, which will enable the company to complete a phase IIb trial of its lead drug candidate, the inhaled galectin-3 inhibitor GB-0139, in idiopathic pulmonary fibrosis, and to move two other programs into phase II studies, in liver fibrosis and myelofibrosis, before year-end.
PERTH, Australia – Sydney-based Recce Pharmaceuticals Ltd. completed a placement of AU$27.95 million (US$19.69 million) to advance its synthetic anti-infective pipeline to address antibiotic-resistant superbugs and emerging viral pathogens.
Nutcracker Therapeutics Inc., a startup developing a "push-button GMP-in-a-box" platform to manufacture mRNA therapeutics, has raised $60 million in series B financing led by Arch Venture Partners.
RSS
